Company: LBRX
Filing Date: 2025-08-22
Form Type: S-1
Source: 0001193125-25-186467
Chunk: 113

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-08-22
Form: S-1
Chunk 113
---
 by using our shares of common stock as consideration.

In
addition, if, after listing, we fail to satisfy the continued listing requirements of Nasdaq, such as the corporate governance requirements or the minimum closing bid price requirement, Nasdaq may take steps to delist our common stock. Such a
delisting would likely have a negative effect on the price of our common stock and would impair your ability to sell or purchase our common stock when you wish to do so. In the event of a delisting, we can provide no assurance that any action taken
by us to restore compliance with listing requirements would allow our common stock to become listed again, stabilize the market price or improve the liquidity of our common stock, prevent our common stock from dropping below the Nasdaq minimum bid
price requirement or prevent future non-compliance with the listing requirements of Nasdaq.

71

Our quarterly and annual operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts or any guidance we may publicly provide, each of which may cause our stock price to fluctuate or decline. We expect our operating results to be subject to quarterly and annual fluctuations which may, in turn, cause the price of our common stock to fluctuate substantially. Our net loss and other operating results will be affected by numerous factors, including:

| • |     | variations in the level of expense related to the ongoing development of 
 LB-102 or future development programs;                                   |

| • |     | results and timing of preclinical studies and ongoing and future clinical trials, or the addition or termination 
 of any such clinical trials;                                                                                     |

| • |     | the timing of payments we may make or receive under existing license and collaboration arrangements or the 
 termination or modification thereof;                                                                       |

| • |     | our execution of any strategic transactions, including acquisitions, collaborations, licenses, or similar        
 arrangements, and the timing and amount of payments we may make or receive in connection with such transactions; |

| • |     | any intellectual property infringement lawsuit or opposition, interference, or cancellation proceeding in which 
 we may become involved;                                                                                         |

| • |     | recruitment and departures of key personnel; |

| • |     | if our product candidate receives regulatory approval in the future, the terms of such approval, and market 
 acceptance and demand for such products;                                                                    |

| • |     | regulatory developments affecting our product candidate or those of our competitors; |

| • |     | global or regional public health emergencies, including any health epidemics